US FDA drug approvals in oncology: the latest news

Written by Jade Parker, Senior Editor
Drug approvals Drug development How I treat... Industry and business News
US FDA

In our ongoing roundup article, we cover the latest oncology drugs being approved by the US FDA. Read on to discover what new therapeutic options are emerging for a range of cancer types. Encorafenib with cetuximab and mFOLFOX6 Approved: 20 December 2024 Indication: Metastatic colorectal cancer with a BRAF V600E mutation One of the first FDA approvals granted under Project FrontRunner happened at the end of December. Project FrontRunner, an initiative by the FDA Oncology Center of Excellence, encourages drug developers to seek approval for cancer treatments earlier in the clinical timeline, targeting advanced or metastatic disease, rather than focusing...

To view this content, please register now for access

It's completely free